Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma.
10.5021/ad.2011.23.S3.S404
- Author:
Mun Ki CHOI
1
;
Hyun Young WOO
;
Jeong HEO
;
Mong CHO
;
Gwang Ha KIM
;
Geun Am SONG
;
Moon Bum KIM
Author Information
1. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea. jheo@pusan.ac.kr
- Publication Type:Case Report
- Keywords:
Hepatocellular carcinoma;
Sorafenib;
Tosufloxacin;
Toxic epidermal necrolysis
- MeSH:
Adrenal Cortex Hormones;
Adult;
Bays;
Carcinoma, Hepatocellular;
Early Intervention (Education);
Epidermal Necrolysis, Toxic;
Female;
Fluoroquinolones;
Humans;
Naphthyridines;
Niacinamide;
Phenylurea Compounds
- From:Annals of Dermatology
2011;23(Suppl 3):S404-S407
- CountryRepublic of Korea
- Language:English
-
Abstract:
This is the first case report to describe a 44-year-old woman with a history of advanced hepatocellular carcinoma who developed toxic epidermal necrolysis (TEN) clinically after taking 400 mg sorafenib (Nexavar(R), BAY 43-9006) and tosufloxacin orally once per day. Both sorafenib and tosufloxacin were eventually discontinued, and the TEN resolved with corticosteroids and supportive treatment. Clinical physicians should be aware of this possible complication so that early interventions can be made.
